Introduction: In recent years, the pharmaceutical industry has faced several major product recalls linked to nitrosamine contamination. A detailed Nitrosamine […]
Trending Nitrosamine Recalls: Lessons Learned from Global Regulatory Actions Read More »
Introduction: Outsourced Bioanalysis Services help biotech startups reach the clinic faster by providing ready-to-deploy analytical expertise, infrastructure, and regulatory support—without
How Outsourced Bioanalysis Improves Speed-to-Clinic for Startups Read More »
Introduction: An Integrated Chemistry and Bioanalytical CRO model unifies synthetic chemistry, analytical characterization, and bioanalytical services into a single scientific
Integrating Bioanalytical and Chemistry Services in Drug Discovery CRO Models Read More »
Introduction Nitrosamine Testing for OTC Products demands a risk-based and stability-focused approach that goes beyond traditional impurity testing. Over-the-counter medicines
Nitrosamine Testing for Over-the-Counter (OTC) Products: Special Considerations Read More »
Introduction Nitrosamine Testing in Combination Products presents greater scientific and regulatory challenges than testing single-API drug products. When multiple APIs
Nitrosamine Testing in Combination Drug Products: Managing Multiple APIs Read More »
Introduction: A Bioanalytical CRO for AI drug discovery plays a critical role in transforming AI-generated hypotheses into validated, regulatory-ready drug
How Bioanalytical CROs Support AI-Driven Drug Discovery Services Read More »
Introduction In pharmaceutical manufacturing, understanding Nitrosamine Alert Limit vs Action Limit is critical for compliance and patient safety. The distinction
Setting Alert Limits vs Action Limits for Nitrosamines: Practical Implementation Guide Read More »
Introduction: The Nitrosamine Batch Release Testing Requirement becomes mandatory when confirmatory testing shows nitrosamine impurity levels above 10% of the
Nitrosamine Batch Release Testing: When Is Routine Testing Required? Read More »
Introduction: The Octreotide Sameness Study for ANDA submission is a critical regulatory requirement when filing a generic octreotide product with
Case Study: Sameness Evaluation of Octreotide Generic project submission to USFDA Read More »
Introduction: The Liraglutide Sameness Study for ANDA submission is a critical regulatory requirement when filing a generic version of liraglutide
Case Study: Sameness Evaluation of Liraglutide Generic project submission to USFDA Read More »
